This combination incorporates immune and metabolic factors, not only accurately predicting the prognosis, but also distinguishing different glioma molecular subtypes, including IDH1 mutation, MGMT promoter methylation, and 1p/19q co-deletion. The gene discussed is MGMT; the disease is central nervous system cancer.